Policy

Insights

News

BIO Launches “The Fight of Our Lives,” a National Campaign to Spotlight the Impact of Biotechnology on the Lives of Patients and Families

April 15, 2026

John F. Crowley's Annual Letter to BIO Membership

April 8, 2026

BIO Statement on the Section 232 Pharmaceutical Proclamation

April 2, 2026

BIO Statement on Passage of Legislation Reauthorizing the SBIR/STTR Program

March 17, 2026

Letters, Comments & Testimony

John F. Crowley's Annual Letter to BIO Membership

April 8, 2026

Dear Colleagues, I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great innovation stories in human history. From the earliest…

BIO Comments on Global Benchmark for Efficient Drug Pricing (GLOBE) Model (CMS-5545-P)

February 23, 2026

BIO Comments on Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (CMS-5546-P)

February 23, 2026

Co-Pay Accumulator Programs

Insurers and PBMs are implementing “co-pay accumulator” programs – an effort to prevent funds provided by manufacturer assistance programs from…

International Reference Pricing

Adopting foreign price controls on innovative medicines would severely chill investment in new cures and therapies for diseases and jeopardize access…